

## Abbreviated New Drug Application (ANDA) Meeting Requests

#### Tina T. Nhu, Pharm.D., R.Ph.

Commander, U.S. Public Health Service Team Leader Regulatory Project Manager Division of Project Management Office of Generic Drugs |CDER | U.S. FDA

April 12, 2023

## **Overview**

FDA

- GDUFA II vs. GDUFA III
- Meeting Types and Meeting Requests
- Meeting Package
- Evaluating Meeting Requests: Grant/Deny
- Rescheduling and Canceling Meetings
- Industry and FDA Responsibilities

### **Guidance for Industry**

Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA Guidance for Industry

> U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

> > October 2022 Generic Drugs

> > > **Revision** 1

- Meeting Types
- Meeting Requests
- Evaluating Meeting Requests
- Rescheduling and Canceling Meetings
- Meeting Package Content and Submission

FD/A

## **GDUFA II**



#### GDUFA II Established a Pre-ANDA Program for Complex Generic Drug Products

Applicants granted a Product Development Meeting OR a Pre-submission Meeting had the option of a Mid-Review Cycle Meeting (MRCM)



#### Clarify regulatory expectations in early development

Assist applicants with developing more complete submissions

More efficient/effective review process

Reduce number of review cycles

#### **GDUFA III**



#### Enhanced pathway for complex products

Assist in generating and submitting to FDA a meeting request for complex products

Unified approach to formal meetings

Robust advice to meet the standards for ANDA approval

#### **Meeting Types for Complex Products**



Product Development Meetings

#### Pre-Submission Meetings

#### Mid-Cycle Review Meetings (MCRM)

Enhanced Mid-Cycle Review Meetings (EMCRM)

Post-CRL Scientific Meeting (Post CRL)

### **Meeting Formats**



Teleconferences	<ul> <li>Teleconferences are meetings conducted verbally via telephone.</li> </ul>
Videoconference	<ul> <li>Videoconferences are meetings in which attendees participate from various remote locations via a video connection.</li> </ul>
Face-to-Face	<ul> <li>Face-to-face meetings are those in which most attendees participate in person at the FDA.</li> </ul>
Written Responses only	<ul> <li>Responses are sent in lieu of a teleconference, videoconference, or face-to-face.</li> </ul>

# **Meeting Requests**

- Electronic submission pathways
  - CDER NextGen Collaboration Portal
  - Electronic Submission Gateway (ESG)
- If the meeting request does not contain criteria specified in Section V of the guidance, the request will not be considered to be submitted for purposes of GDUFA III performance goals.

Reference – Section V (page 10) of the Formal Meeting Between FDA and ANDA Applicants of Complex Products Under GDUFA, Guidance for Industry



# **Meeting Request Granted**

- FDA
- FDA will send a written notification of the decision to the applicant
- If FDA plans to hold a meeting or teleconference, scheduling information will be included in the meeting grant letter or forwarded to the applicant as soon as possible
- Meeting may be partially granted
  - e.g., if the meeting package contains questions not appropriate for the meeting type or questions that are out of scope of the meeting type
- FDA will advise the applicant if a written response only is forthcoming


# **Meeting Request Denied**

- If criteria not met
- If meeting request is denied
  - Agency will notify the applicant in writing and provide a rationale
  - A subsequent meeting request will be considered as a new request


# **Meeting Request Denied**


- Does not meet the criteria for a complex product or because a meeting is premature for the stage of product development in light of insufficiency of the data generated.
- An MCRM or EMCRM request may be denied if the applicant did not participate in a prior product development meeting or presubmission meeting, or the product does not meet the criteria for a complex product. In addition, if the request is made before issuance of the last mid-cycle DRL or the request is made more than 7 days after the issuance of the last mid-cycle DRL.
- A post-CRL scientific meeting request may be denied because the product does not meet the criteria for a complex product.

- Agency will notify the applicant in writing and provide a rationale
- A subsequent meeting request will be considered as a new request



www.fda.gov





#### www.fda.gov

### **Canceled Meeting**

Applicant cancels the meeting after preliminary responses are received (will count towards meeting performance goal)

FDA cancels the meeting (will not count towards meeting performance goal)

FDA's discretion for meeting cancelation depending on the specific situation

Subsequent request to schedule a meeting will be considered a new meeting request

# FDA

### **Rescheduled Meetings**

If necessary, FDA will work to reschedule as soon as possible


A new meeting request should NOT be submitted

If applicant requests to reschedule, FDA will assess

If FDA reschedules, FDA will notify the applicant of the reason




# What Can Industry Do To Assist



# What Should Industry Expect?







#### Impact of these meetings

Enhanced engagement Reduced number of review cycles Decreased time from ANDA acceptance to approval More competition, increased access to generic drugs

www.fda.gov

#### Resources



- **GDUFA III Commitment Letter:** 
  - GDUFA Reauthorization Performance Goals and Program Enhancements Fiscal Years 2023-2027
- Guidance for Industry:
  - Guidance on Formal Meetings between FDA and ANDA Applicants of Complex Products Under GDUFA
  - Draft guidance on Product-Specific Guidance Meetings Between FDA and ANDA Applicants Under GDUFA
  - Guidance on Post-Complete Response Letter Clarification Teleconferences Between FDA and ANDA Applicants Under GDUFA



### For questions, please contact the Regulatory Project Manager assigned to the respective ANDA

